Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IB-T101 in Advanced Clear Cell Renal Cell Carcinoma
NCT06819293Phase 1Recruiting
- Sponsor
- Grit Biotechnology
- Start
- Dec 2024
- Primary completion
- Dec 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IB-T101 in clear cell renal cell carcinoma (ccRCC), sponsored by Grit Biotechnology. Primary endpoints: Objective Response Rate at 3 years and Adverse Events at 3 years. Started Dec 2024; status: recruiting.
02
Drugs
IB-T101
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT06819293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06819293.